Name: AETERNA ZENTARIS INC (AEZS) Stock
Brand: AETERNA ZENTARIS INC
Rating: 3 (3 reviews)

AEZS Latest News, Press Relases and Analysis

All

Press Releases

a year ago - By: Aeterna Zentaris Inc - Mentions: AEZS.CA

Aeterna Zentaris Inc. Announces Name Change to COSCIENS Biopharma Inc.

a year ago - By: Aeterna Zentaris Inc - Mentions: AEZS.CA

Aeterna Zentaris Announces Results of Virtual 2024 Meeting of Shareholders

a year ago - By: Aeterna Zentaris Inc - Mentions: AEZS.CA

Aeterna Zentaris Announces Last Patient Last Visit in Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

a year ago - By: Ademi LLP

Shareholder Alert: Ademi LLP investigates whether Aeterna Zentaris Inc.'s transaction with Ceapro was Fair to Shareholders

a year ago - By: Ceapro Inc. - Mentions: CZO.CA AEZS.CA

Aeterna Zentaris and Ceapro Complete Merger Transaction

a year ago - By: BusinessInsider

AEZS Stock Earnings: AEterna Zentaris Misses EPS, Misses Revenue for Q1 2024

2 years ago - By: InvestorPlace

AEZS Stock Earnings: AEterna Zentaris Misses EPS for Q4 2023

2 years ago - By: Benzinga

AEterna Zentaris: Q4 Earnings Insights

a year ago - By: Aeterna Zentaris Inc - Mentions: AEZS.CA

Aeterna Zentaris and Ceapro Complete Merger Transaction

a year ago - By: Aeterna Zentaris Inc - Mentions: AEZS.CA

Aeterna Zentaris Provides Update on Timing for Annual Meeting of Shareholders and Due Bill Redemption Date

a year ago - By: Aeterna Zentaris Inc - Mentions: AEZS.CA

Aeterna Zentaris Announces Details Regarding Transaction with Ceapro

a year ago - By: InvestorPlace

AEZS Stock Earnings: AEterna Zentaris Misses EPS, Misses Revenue for Q1 2024

a year ago - By: Aeterna Zentaris Inc - Mentions: AEZS.CA

Aeterna Zentaris Reports First Quarter 2024 Financial Results

2 years ago - By: Aeterna Zentaris Inc - Mentions: AEZS.CA

Aeterna Zentaris Announces Effective Date of Share Consolidation

3 years ago - By: Benzinga - Mentions: NVO

Aeterna Zentaris Shelves Early-Stage Vaccine Programs, Including COVID-19

2 years ago - By: Ceapro Inc. - Mentions: CZO.CA AEZS.CA

Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris

2 years ago - By: Aeterna Zentaris Inc - Mentions: AEZS.CA

Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

2 years ago - By: Ceapro Inc.; Aeterna Zentaris Inc. - Mentions: CZO.CA AEZS.CA

Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings

2 years ago - By: Ceapro Inc. - Mentions: CZO.CA AEZS.CA

Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company

2 years ago - By: Aeterna Zentaris Inc - Mentions: AEZS.CA

Aeterna Zentaris Issues Letter to Shareholders and Management Proxy Circular Ahead of Special Meeting of Shareholders to Approve Merger of Equals with Ceapro

2 years ago - By: Seeking Alpha

Aeterna Zentaris files to sell 2.53M warrants (NASDAQ:AEZS)

2 years ago - By: Halper Sadeh LLC

AEZS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Aeterna Zentaris Inc. Is Fair to Shareholders

2 years ago - By: Seeking Alpha

Aeterna Zentaris and Ceapro to merge in all-stock deal

2 years ago - By: Aeterna Zentaris Inc - Mentions: AEZS.CA

Aeterna Zentaris and Ceapro Announce Merger of Equals to Create a Diversified Biopharmaceutical Company

2 years ago - By: Aeterna Zentaris Inc - Mentions: AEZS.CA

Aeterna Zentaris Reports Second Quarter 2023 Financial Results

2 years ago - By: Aeterna Zentaris Inc - Mentions: AEZS.CA

Aeterna Zentaris Outlines Progress on Development Pipeline Programs and Provides Corporate Update

2 years ago - By: Aeterna Zentaris Inc - Mentions: AEZS.CA

Aeterna Zentaris to Participate in the Virtual Investor Summer Spotlight Series

2 years ago - By: Aeterna Zentaris Inc - Mentions: AEZS.CA

Aeterna Zentaris Announces Results of Virtual 2023 Meeting of Shareholders

2 years ago - By: Aeterna Zentaris Inc - Mentions: AEZS.CA

Aeterna Zentaris Reports First Quarter 2023 Financial Results

3 years ago - By: Aeterna Zentaris Inc - Mentions: AEZS.CA

Aeterna Zentaris Provides Update on Macrilen® (Macimorelin), Reiterates Advancement of Pediatric DETECT Trial

3 years ago - By: Aeterna Zentaris Inc - Mentions: AEZS.CA

Aeterna Zentaris Reports Fourth Quarter and Full Year 2022 Financial Results

3 years ago - By: Aeterna Zentaris Inc - Mentions: AEZS.CA

Pharmanovia to Market GHRYVELIN™ (Macimorelin) in the European Economic Area (EEA) and UK as Diagnostic Test for Growth Hormone Deficiency (GHD)

3 years ago - By: Aeterna Zentaris Inc - Mentions: AEZS.CA

Aeterna Zentaris Provides Business Update and Outlines Key Upcoming Milestones

3 years ago - By: Aeterna Zentaris Inc - Mentions: AEZS.CA

Aeterna Zentaris to Present at the Virtual Investor 2023 Companies to Watch Event

3 years ago - By: Aeterna Zentaris Inc - Mentions: AEZS.CA

AETERNA ZENTARIS INC (AEZS) Stock News

AEZS Latest News, Press Relases and Analysis

Aeterna Zentaris Inc. Announces Name Change to COSCIENS Biopharma Inc.

Aeterna Zentaris Announces Results of Virtual 2024 Meeting of Shareholders

Aeterna Zentaris Announces Last Patient Last Visit in Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

Shareholder Alert: Ademi LLP investigates whether Aeterna Zentaris Inc.'s transaction with Ceapro was Fair to Shareholders

Aeterna Zentaris and Ceapro Complete Merger Transaction

AEZS Stock Earnings: AEterna Zentaris Misses EPS, Misses Revenue for Q1 2024

AEZS Stock Earnings: AEterna Zentaris Misses EPS for Q4 2023

AEterna Zentaris: Q4 Earnings Insights

Aeterna Zentaris and Ceapro Complete Merger Transaction

Aeterna Zentaris Provides Update on Timing for Annual Meeting of Shareholders and Due Bill Redemption Date

Aeterna Zentaris Announces Details Regarding Transaction with Ceapro

AEZS Stock Earnings: AEterna Zentaris Misses EPS, Misses Revenue for Q1 2024

Aeterna Zentaris Reports First Quarter 2024 Financial Results

Aeterna Zentaris Announces Effective Date of Share Consolidation

Aeterna Zentaris Shelves Early-Stage Vaccine Programs, Including COVID-19

Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris

Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings

Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company

Aeterna Zentaris Issues Letter to Shareholders and Management Proxy Circular Ahead of Special Meeting of Shareholders to Approve Merger of Equals with Ceapro

Aeterna Zentaris files to sell 2.53M warrants (NASDAQ:AEZS)

AEZS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Aeterna Zentaris Inc. Is Fair to Shareholders

Aeterna Zentaris and Ceapro to merge in all-stock deal

Aeterna Zentaris and Ceapro Announce Merger of Equals to Create a Diversified Biopharmaceutical Company

Aeterna Zentaris Reports Second Quarter 2023 Financial Results

Aeterna Zentaris Outlines Progress on Development Pipeline Programs and Provides Corporate Update

Aeterna Zentaris to Participate in the Virtual Investor Summer Spotlight Series

Aeterna Zentaris Announces Results of Virtual 2023 Meeting of Shareholders

Aeterna Zentaris Reports First Quarter 2023 Financial Results

Aeterna Zentaris Provides Update on Macrilen® (Macimorelin), Reiterates Advancement of Pediatric DETECT Trial

Aeterna Zentaris Reports Fourth Quarter and Full Year 2022 Financial Results

Pharmanovia to Market GHRYVELIN™ (Macimorelin) in the European Economic Area (EEA) and UK as Diagnostic Test for Growth Hormone Deficiency (GHD)

Aeterna Zentaris Provides Business Update and Outlines Key Upcoming Milestones

Aeterna Zentaris to Present at the Virtual Investor 2023 Companies to Watch Event

Aeterna Zentaris Reports Third Quarter 2022 Financial Results